Exenatide

Exendin-4 (Byetta/Bydureon)

39 Amino Acids · MW: 4,186.57 Da

Ask AI About This

Amino Acids

Molecular Weight

4,186.57 Da

Half-life

~2.4 hours (Byetta) / weeks (Bydureon)

Research Score

4.5

Studies

670

Storage

N/A

What is Exenatide?

Exenatide is a GLP-1 receptor agonist originally derived from the saliva of the Gila monster lizard. FDA-approved as Byetta (twice daily) and Bydureon (once weekly) for type 2 diabetes. It was the first commercially available GLP-1 receptor agonist and paved the way for the entire drug class.

Key Benefits & Mechanisms

First-in-class GLP-1 agonist

FDA-approved for type 2 diabetes

Weight loss (modest)

Improved glycemic control

Once-weekly formulation available

Cardiovascular neutral (EXSCEL trial)

Well-established safety profile

Research Summary

Exenatide has extensive clinical evidence from multiple Phase III programs. FDA-approved since 2005. EXSCEL cardiovascular outcomes trial showed non-inferiority. While newer GLP-1 agents have surpassed it for weight loss, it remains an important therapeutic option with a long safety track record.

Related Peptides

Semaglutide

GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Metabolic

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic